#bioconbiologics search results
Deepali Naair appointed Global Head - Brand & Corporate Communications at @BioconBiologics . She will lead the global brand and corporate communications function. Read the full story: exchange4media.com/people-movemen… #e4m #DeepaliNaair #BioconBiologics #BrandCommunications
Biocon Biologics earns Asia IP Elite 2025 recognition by IAM for the 9th straight year. Strong IP strategy strengthens global biosimilars leadership, innovation moat, and long-term value creation. Positive credibility boost for Biocon. #BioconBiologics #IPLeadership
Branded formulations company #ErisLifesciences Ltd will acquire the domestic branded formulation business of #BioconBiologics, the biosimilar arm of Biocon, for ₹1,242 crore, the two companies said (@Namansuri03 reports) livemint.com/companies/news…
livemint.com
Biocon Biologics to sell India branded formulations biz to Eris Lifesciences for ₹1,242 cr |...
The deal will facilitate Eris's entry into the injectables market in India, bringing major insulin brands Basalog and Insugen into the company
- कंपनी का क्या है Growth OutLook? - Adalimumab Drug में कब तक आ सकती है तेजी? देखिए #BioconBiologics के CEO & MD श्रीहास तांबे से खास बातचीत #StockMarket @tweet2prashant @poojat_0211
ET NOW स्वदेश ON THE GO- बंगलुरु एडिशन #BioconBiologics का कैसा रहा सफर और अधिग्रहण के बाद क्या कुछ बदला? कितने देशों में है कंपनी की मौजूदगी? कारोबार विस्तार और ग्रोथ को लेकर क्या है आउटलुक? देखिए @BioconBiologics के MD & CEO, श्रीहास तांबे से खास बातचीत #SwadeshOnTheGo
#BioconBiologics secures $300 million loan from HSBC and Mizuho Bank to refinance debt for Viatris acquisition. The floating rate loan is priced at 6.34%. #Viatris #Healthcare #InvestmentStrategies economictimes.indiatimes.com/markets/stocks…
economictimes.indiatimes.com
Biocon Biologics raises $300 million for debt refinancing
The loan was priced at 175 basis points above the three-month secured overnight funding rate (SOFR), which was trading at 4.59%. That pegs the floating-rate loan at 6.34%, people familiar with the...
#JustIn | #Biocon to fully integrate #BioconBiologics as its wholly-owned subsidiary, subject to approvals ▶️Co to acquire remaining stake in Biocon Biologics via share swap, valuing it at $5.5 bn ▶️Biocon to acquire Mylan’s (#Viatris) remaining stake for $815 m, including a
#Biocon to fully integrate #BioconBiologics; to acquire #Viatris’ remaining stake via share swap @anshul91_m @ekta_batra cnbctv18.com/market/stocks/…
#Biocon Biologics secures #USFDA approval for its biosimilar Aflibercept, branded as Yesafili™. This milestone marks their entry into the US ophthalmology market! 👁️💉 #BioconBiologics #FDAApproval #Ophthalmology #Biosimilar #Yesafili #HealthcareInnovation #PharmaNews
#StocksInNews | ##SERUM और #BIOCONBIOLOGICS के साथ करार पर कई सवाल, अब मैनेजमेंट से क्लेरिटी का है इंतजार.... @_anujsinghal @YatinMota @AEHarshada
The FDA approved Kirsty, Biocon Biologics’ first interchangeable NovoLog biosimilar insulin aspart in the US. Our article explores its role in diabetes care and related growth in the biosimilar market at buff.ly/GRZ2t9U by @soumya2390. #BioconBiologics #Kirsty
#Biocon raises stake in #BioconBiologics to 98% after completing $200 million share buyout @jpullokaran buff.ly/fqtigDE
#JustIn | #BioconBiologics refinances ₹9,346 cr long-term debt through USD bonds & new syndicated facility
U.S. FDA Completes Inspection at Biocon Biologics' Facility at Biocon Campus, Bengaluru, India @Bioconlimited @BioconBiologics #USFDA #Inspection #BioconBiologics #Facility #BioconCampus #Bengaluru #India equitybulls.com/category.php?i…
Biocon Biologics inks pact with Sandoz for sale of 2 biosimilar products in Australia #bioconbiologics | #sandoz | #biosimilars | #australia | #healthnews Read more: health.economictimes.indiatimes.com/news/pharma/ph…
#BioconBiologics, a subsidiary of #Biocon, has signed a distribution agreement with #Sandoz for an immunity-linked injection in Japan. |@chit_ranjan fortuneindia.com/investing/bioc… #BioconSandozdeal #FKBinjection #Biopharma #pharma #stock #sharemarket
#Fitch revises #BioconBiologics outlook to Positive, affirms rating at BB- @TheAsmitaPant cnbctv18.com/business/fitch…
#BioconBiologics sees strong FY27 as new biosimilars gain traction cnbctv18.com/business/compa…
With the new arrangement, #BioconBiologics will have access to 100 million doses of vaccines annually together with the distribution rights to #Serum's vaccine portfolio. (@ranjanir_ reports) livemint.com/companies/news…
#3QWithCNBCTV18 | ‘Expect 20%+ #EBITDA margin going forward,’ says Shreehas Tambe, MD & CEO of #BioconBiologics, after the company reports a weak set of Q3 earnings. Tells @vinnii_motiwala that they are focussing on key therapies like #oncology, #auto-immune and #insulin. WATCH
🔥 Biocon Biologics: A 2026 Play Turning From Capacity to Cash Flow Read More: tinyurl.com/mvcps5ba #BioconBiologics #FinancialInsights #EquityResearch #Biotech #MedicalInnovation #InstitutionalInvesting #IndiaMarkets #EarningsMomentum #InvestorView
Biocon renames Irish step-down subsidiary as Biocon Biologics Ireland indianpharmapost.com/biotech/biocon… #BioconBiologics #Ireland #renaming #biotech #subsidiary #biosimilars #Europe #RajeshU.Shanoy @indpharmapost
Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited #BioconBiologics, #BioconLtd, #BioconLimited, #BIOCON crweworld.com/article/news-p…
Bahiafarma, Biocon Biologics and Bionovis have entered into a memorandum of understanding (MoU) to collaborate in the pharmaceutical sector with a focus on oncology biologics development and manufacturing. Read more: lnkd.in/gfNRhYxW #BahiaFarma #BioconBiologics
#BioconBiologics sees strong FY27 as new biosimilars gain traction cnbctv18.com/business/compa…
Fitch upgrades Biocon Biologics outlook to positive, affirms ‘BB-’ rating indianpharmapost.com/news/fitch-upg… #Fitch #BioconBiologics @indpharmapost
#Fitch revises #BioconBiologics outlook to Positive, affirms rating at BB- @TheAsmitaPant cnbctv18.com/business/fitch…
Biocon Biologics gets credit boost from S&P, outlook stable indianpharmapost.com/news/biocon-bi… #BioconBiologics #biosimilars #Biocon @indpharmapost
indianpharmapost.com
Biocon Biologics gets credit boost from S&P, outlook stable
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
#JustIn | S&P Global upgrades Biocon Arm #BioconBiologics credit rating to ‘BB+’, revises outlook to ‘Stable’ S&P Global Says: ▶️Co’s earnings should grow over next 12–24 months, driven by demand for generics & biosimilars ▶️New launches will support growth & sustain its
#Biocon raises stake in #BioconBiologics to 98% after completing $200 million share buyout @jpullokaran buff.ly/fqtigDE
BIOCON ✅ Company now holds 98% equity share capital in Biocon Biologics ✅ Move strengthens parent’s control and strategic alignment ✅ Enhances focus on biosimilars growth & global expansion ✅ Positive step towards value consolidation #Biocon #BioconBiologics
Biocon completes Rs. 4,150 crore equity fundraise through QIP indianpharmapost.com/news/biocon-co… #MylanInc. #Viatris #BioconBiologics #BioconLimited @indpharmapost
indianpharmapost.com
Biocon completes Rs. 4,150 crore equity fundraise through QIP
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
Biocon Biologics unveils three new oncology biosimilars, eyes $75 billion market opportunity indianpharmapost.com/news/biocon-bi… #BioconBiologics #biosimilars #Biocon #oncology #biosimilar #cancertherapies #44thAnnualJPMorganHealthcareConference #ShreehasTambe @indpharmapost
indianpharmapost.com
Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
2025 was a year of impact. From breakthrough biosimilars to global expansion, Biocon Biologics made healthcare more affordable and accessible for millions worldwide. Click to watch how we made a difference and what we are on track to work towards for 2026! #BioconBiologics
Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference #BioconBiologics, #BioconLtd, #BioconLimited, #BIOCON crweworld.com/article/news-p…
Biocon ✅ Biocon Biologics to expand its biosimilar oncology portfolio ✅ Move strengthens presence in high-growth cancer therapeutics ✅ Supports global market expansion and long-term growth strategy #Biocon #BioconBiologics #Biosimilars #Oncology #PharmaSector
Biocon Biologics Appoints Deepak Dobriyal as Global Head of Talent & HR Transformation youtube.com/shorts/cyruBcp… #BioconBiologics #deepakdobriyal #hrleadership #TalentTransformation #corporateappointments #hrtransformation #peopleleadership @BioconBiologics @StartupERA_IN
youtube.com
YouTube
Startup ERA
Diabetes Awareness Month may have ended, but the responsibility hasn’t. Diabetes doesn’t pause for dates on a calendar. It touches lives every single day — and this reminder matters just as much even after the campaign ends. #BioconBiologics #ClickRight #DiabetesAwareness
#BioconBiologics secures global manufacturing and commercial rights for #Hulio - bit.ly/4p27OzH | #pharma #pharmanews #healthtech #pharmatech #medtech
expresspharma.in
Biocon Biologics secures global manufacturing and commercial rights for Hulio - Express Pharma
Agreement with Fujifilm Kyowa Kirin Biologics covers biosimilar Adalimumab
#JustIn | #BioconBiologics secures #USMarket entry date for #Yesafili, a biosimilar aflibercept. Yesafili is used to treat several different types of Ophthalmology conditions
Biocon Biologics Secures EC’s Approval for Vevzuo and Evfraxy (Biosimilars, Xgeva and Prolia) #bioconbiologics #vevzuo #evfraxy #xgeva #prolia #denosumab #biosimilar pharmashots.com/25841/biocon-b…
Biocon Biologics' Hulio® Biosimilar to Humira®, now available in the United States @Bioconlimited @BioconBiologics #BioconBiologics #Biocon #INE376G01013 #HULIO #Biosimilar #US equitybulls.com/category.php?i…
#Biocon Biologics secures #USFDA approval for its biosimilar Aflibercept, branded as Yesafili™. This milestone marks their entry into the US ophthalmology market! 👁️💉 #BioconBiologics #FDAApproval #Ophthalmology #Biosimilar #Yesafili #HealthcareInnovation #PharmaNews
#BioconBiologics secures strong market access coverage for YESINTEK™ in the US, reaching over 100 million lives through multiple commercial and health plan agreements, including national preferred formulary status with Express Scripts.✌️ #StockMarketIndia
#JustIn | #BioconBiologics refinances ₹9,346 cr long-term debt through USD bonds & new syndicated facility
#BioconBiologics gets U.S. FDA approval for biosimilar aflibercept Yesafili. For the latest news and updates, visit: ndtvprofit.com
🚨Biocon: 👉#BioconBiologics Expands Insulin Access in #Malaysia Over 100 Mn Cartridges of rh-Insulin Supplied to Health Ministry; 345,000+ patients served #Biocon #StockToWatch #StockMarketIndia
#BioconBiologics signs settlement & license agreement to commercialise biosimilar Aflibercept worldwide, this follows an earlier settlement covering the United States & Canada This agreement enables co to launch YESAFILI in the UK in Jan 2026 & in the rest of the settled
Biocon Biologics and Regeneron Settle over Yesafili’s (Biosimilar, Eylea) US Launch pharmashots.com/21756/biocon-b… #bioconbiologics #regeneron #bayer #yesafili #eylea #aflibercept #piii #insight #biosimilar #pharmashots
Serum Institute of India subsidiary Serum Institute Life Sciences has decided to double its investment in Biocon Biologics to $300 mn. @sohinidastweets #SII #BioconBiologics #Biocon bit.ly/3LtJSEQ
#JustIn | Biocon Arm #BioconBiologics secures full global rights to biosimilar #Adalimumab via expanded FKB in-licensing agreement
#SerumInstitute will invest $150 mn in #BioconBiologics as the partners decided to restructure the deal which was inked in 2021. bit.ly/3He54My
#JustIn | #Biocon to fully integrate #BioconBiologics as its wholly-owned subsidiary, subject to approvals ▶️Co to acquire remaining stake in Biocon Biologics via share swap, valuing it at $5.5 bn ▶️Biocon to acquire Mylan’s (#Viatris) remaining stake for $815 m, including a
José Ramón López (#BioconBiologics España): “incluir cada vez más #biosimilares en los servicios asistenciales públicos contribuirá a potenciar el despliegue de estos medicamentos innovadores y a mejorar la resiliencia del #SistemaSanitario español” farmacosalud.com/en-los-hospita…
#CNBCTV18Exclusive | #BioconBiologics & #Biocon will see synergies such as supply chain procurement, mandated #MorganStanley to see at steps for value unlocking. Strategic investors unlikely to influence the journey of biologics co, says #KiranMazumdarShaw of Biocon
Biocon Biologics Join Forces with Civica to extend access of Insulin Aspart in the US pharmashots.com/21311/biocon-b… #bioconbiologics #civica #insulinaspart #us #commercialization #drugproductmanufacturing #drugsubstancesupply #technologytransfer #usfda #pharma #pharmashots
#StockInNews | S&P Global places Biocon Biologics on Positive CreditWatch following accelerated debt reduction #BioconBiologics #SPGlobal #CreditWatch #DebtReduction #PharmaUpdate #CorporateFinance
#Biocon raises stake in #BioconBiologics to 98% after completing $200 million share buyout @jpullokaran buff.ly/fqtigDE
Deepali Naair appointed Global Head - Brand & Corporate Communications at @BioconBiologics . She will lead the global brand and corporate communications function. Read the full story: exchange4media.com/people-movemen… #e4m #DeepaliNaair #BioconBiologics #BrandCommunications
Something went wrong.
Something went wrong.
United States Trends
- 1. #KentuckyDerby N/A
- 2. Tatum N/A
- 3. Spirit N/A
- 4. So Happy N/A
- 5. Great White N/A
- 6. Further Ado N/A
- 7. Chief Wallabee N/A
- 8. Jaylen Brown N/A
- 9. JetBlue N/A
- 10. Reds N/A
- 11. Emerging Market N/A
- 12. My Old Kentucky Home N/A
- 13. New Day N/A
- 14. Tucker N/A
- 15. Kyle Larson N/A
- 16. Ask Jeeves N/A
- 17. Danon Bourbon N/A
- 18. Kofi N/A
- 19. Commandment N/A
- 20. Austin Hedges N/A